Will Lewis, Insmed CEO, joins 'Fast Money' to discuss the company's lung drug being greenlit by the FDA and what it means for ...

The U.S. Food and Drug Administration has approved Insmed's oral drug for a type of lung disease, the company said on Tuesday ...

A first-in-class reversible dipeptidyl peptidase-1 (DPP-1) inhibitor, brensocatib addresses the underlying inflammatory ...

The U.S. Food and Drug Administration has approved Insmed's oral drug for a type of lung disease, the company said on Tuesday ...

Parents in the United States who want to vaccinate their young children against Covid-19 this fall may face a growing set of ...

For most Americans, the letters "NTM" don’t mean anything. But for tens of thousands of people across the country, they ...

Brinsupri, which Insmed acquired from AstraZeneca nearly a decade ago, is the first treatment for bronchiectasis that’s not ...

PureTech Health has launched a subsidiary company – Celea Therapeutics – with the task of taking an experimental drug for ...

The spinout, known as Celea Therapeutics, will advance what’s designed to be an improved version of the drug pirfenidone for ...

Janet Pope, MD, MPH, discusses screening and diagnostic approaches for interstitial lung disease in patients with systemic ...

The diagnosis of chronic obstructive pulmonary disease, or COPD, is improved by incorporating CT lung imaging and respiratory ...